No Data
Press Release: Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Express News | Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Express News | Stephens & Co. Reiterates Overweight on Nurix Therapeutics, Maintains $31 Price Target
Nurix Therapeutics Analyst Ratings
BTIG Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $35
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
EmotionOutofEquation : Already 500% current year where is yearly bottom of strong buy potential
EmotionOutofEquation : Time to make separate watchlist of strong buys so get better cost price for less red days